Rezolute, Inc.

RZLT Healthcare Biotechnology

In the quarter to June 2026, EPS grew 23.1% and free cash flow grew 40.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.58 0.32 −8.21%
Market cap
$377.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(59.23%) (74.02%) (81.73%) (59.04%)
ROA
(54.73%) (67.21%) (74.01%) (53.82%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(53.39%) (67.04%) (71.23%) (78.26%)
Free Cash Flow per Share
(0.68) (0.74) (0.71) (0.62)
Free Cash Flow
(70.49) (77.15) (73.48) (64.63)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Oct 2026